SRC and Peritoneal Fibrosis: In this study, we demonstrated that (i) Src kinase is activated in cultured HPMCs and in the fibrotic peritoneum; (ii) pharmacological inhibition with KX2-391 or silencing of Src reduces the EMT of HPMCs; (iii) administration of KX2-391 reduces peritoneal fibroblast activation and attenuates accumulation of ECM in the rat model of peritoneal fibrosis induced by CG injury.